CB2 Receptor: nootropics and compounds | sci-wiki

Cannabichromene

Cannabichromene (CBC) is a non-psychotropic phytocannabinoid and one of the six most abundant cannabinoids in Cannabis sativa, biosynthesized from cannabigerolic acid (CBGA) via the enzyme CBCA synthase and decarboxylated from its acidic precursor cannabichromenic acid. Structurally a resorcinol-derived chromene rather than the classic dibenzopyran of THC, it binds the classical cannabinoid receptors only weakly and instead acts primarily as a potent agonist of the TRPA1 ion channel while inhibiting the cellular reuptake and degradation of the endocannabinoid anandamide. Preclinical studies describe anti-inflammatory, gastrointestinal-normalizing, antidepressant-like, analgesic, antimicrobial and neural stem-cell-supporting activity, and CBC is frequently cited as a contributor to the "entourage effect" of whole-plant cannabis. It is not scheduled as a distinct controlled substance in most jurisdictions but is regulated as a cannabis constituent, and its clinical evidence base in humans remains early-stage.

reference

Cannabinoid

HU-210

HU-210 is a synthetic cannabinoid that acts as an ultra-potent full agonist at both the CB1 and CB2 cannabinoid receptors. It is the (6aR,10aR) enantiomer of the 1,1-dimethylheptyl homolog of 11-hydroxy-delta-8-tetrahydrocannabinol, developed in the 1980s by Raphael Mechoulam's group at the Hebrew University of Jerusalem (the source of the "HU" prefix). Structurally a close analog of THC, HU-210 is estimated to be roughly 100 to 800 times more potent than delta-9-THC, with sub-nanomolar affinity at CB1 and a notably long duration of action. It has been used primarily as a pharmacological tool compound to probe the endocannabinoid system in preclinical models, and has also appeared as an adulterant in illicit "herbal incense" (Spice/K2) products. HU-210 is controlled as a Schedule I substance in the United States and is not an approved medicine.

reference

Cannabinoid

JWH-210

JWH-210 is a synthetic cannabinoid of the naphthoylindole class that acts as a potent agonist at both cannabinoid receptors, CB1 and CB2. It was created during academic research into cannabinoid structure and pharmacology and later appeared as an active ingredient in illicit herbal smoking blends sold as synthetic cannabis [1][2]. It has no approved medical use and is controlled as an illegal substance in many countries [2].

reference

Synthetic Cannabinoid

MDMB-4en-PINACA

MDMB-4en-PINACA is a synthetic cannabinoid, an indazole carboxamide sold sprayed onto plant material and into vape liquid. ⚠️ It is not strong cannabis. THC is a partial agonist at the CB1 receptor and therefore has a ceiling; this is a full agonist and has none, reaching roughly 2.4 times THC's maximum effect and about 27 times its potency in the same experiment [1]. In the largest clinical series, 81 percent of presentations involved reduced consciousness and 30 percent involved seizures [3].

reference

Cannabinoid

Nabilone

Nabilone is a synthetic cannabinoid (a structural analog of delta-9-tetrahydrocannabinol) that acts as an agonist at the cannabinoid CB1 and CB2 receptors. Marketed as Cesamet, it is approved in the United States, Canada, the United Kingdom and other countries for the treatment of severe nausea and vomiting associated with cancer chemotherapy that has failed to respond to conventional antiemetics. Unlike inhaled cannabis or plant-derived THC, nabilone is a single, orally administered, pharmaceutically standardized molecule, which gives it consistent dosing and a defined pharmacokinetic profile. Beyond its licensed antiemetic indication, it has been studied off-label for neuropathic and chronic non-cancer pain, fibromyalgia, PTSD-associated nightmares, and agitation in Alzheimer's disease, with mixed but frequently encouraging results. Nabilone is a Schedule II controlled substance in the United States and a prescription-only medicine.

reference

Cannabinoid

WIN 55,212-2

WIN 55,212-2 is a synthetic aminoalkylindole cannabinoid receptor agonist that binds and fully activates both the CB1 and CB2 cannabinoid receptors, and is one of the most widely used reference agonists in endocannabinoid pharmacology. Developed by Sterling Winthrop from the aminoalkylindole (pravadoline) series while researchers were pursuing non-steroidal anti-inflammatory analgesics, it is structurally unrelated to plant-derived cannabinoids like THC yet produces overlapping in vivo effects including antinociception, hypothermia, catalepsy and hypomotility. It is a laboratory tool compound rather than an approved medicine, valued because it is a high-potency full agonist with slight CB2 preference and because its two enantiomers (the active R(+) form versus the near-inactive S(-) WIN 55,212-3) allow clean stereochemical control experiments. It has no approved medical use and is a Schedule I controlled substance in many jurisdictions as a synthetic cannabinoid.

reference